These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16968832)

  • 1. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials.
    Zhang J; Ding EL; Song Y
    JAMA; 2006 Oct; 296(13):1619-32. PubMed ID: 16968832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
    Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.
    Curtis E; Fuggle N; Shaw S; Spooner L; Ntani G; Parsons C; Corp N; Honvo G; Baird J; Maggi S; Dennison E; Bruyère O; Reginster JY; Cooper C
    Drugs Aging; 2019 Apr; 36(Suppl 1):25-44. PubMed ID: 31073922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
    J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis.
    Chan CC; Reid CM; Aw TJ; Liew D; Haas SJ; Krum H
    J Hypertens; 2009 Dec; 27(12):2332-41. PubMed ID: 19887957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative thromboembolic risks associated with COX-2 inhibitors.
    Jones SC
    Ann Pharmacother; 2005; 39(7-8):1249-59. PubMed ID: 15956235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.
    Whelton A
    J Hypertens Suppl; 2002 Sep; 20(6):S31-5. PubMed ID: 12683425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
    Wong M; Chowienczyk P; Kirkham B
    Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain].
    Bijlsma JW; Lems WF; van de Laar MA
    Ned Tijdschr Geneeskd; 2007 Apr; 151(14):795-8. PubMed ID: 17469317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance.
    Ross JS; Madigan D; Hill KP; Egilman DS; Wang Y; Krumholz HM
    Arch Intern Med; 2009 Nov; 169(21):1976-85. PubMed ID: 19933959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis.
    Miao XP; Ouyang Q; Li HY; Wen ZH; Zhang DK; Cui XY
    Curr Ther Res Clin Exp; 2008 Jun; 69(3):181-91. PubMed ID: 24692797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis.
    Lee C; Hunsche E; Balshaw R; Kong SX; Schnitzer TJ
    Arthritis Rheum; 2005 Aug; 53(4):510-8. PubMed ID: 16082648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of selective COX-2 inhibitors.
    Capone ML; Tacconelli S; Sciulli MG; Patrignani P
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the use of non-steroidal anti-inflammatory drugs after cardiac surgery increase the risk of renal failure?
    Acharya M; Dunning J
    Interact Cardiovasc Thorac Surg; 2010 Oct; 11(4):461-7. PubMed ID: 20639308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP; Deray G; Héloire F
    Presse Med; 2006 Sep; 35 Suppl 1():25-34. PubMed ID: 17870550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.
    Andersohn F; Suissa S; Garbe E
    Circulation; 2006 Apr; 113(16):1950-7. PubMed ID: 16618816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R; Baldi C; Di Biase G; Ariano C; Cioppa C; Giasi A; Valente L; Cantatrione S
    Minerva Cardioangiol; 2014 Dec; 62(6):437-48. PubMed ID: 25029569
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.